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ABSTRACT 
During periods of psychosocial distress glucocorticoids (GCs) are known to reduce the lytic 
activity of natural killer cells (NKCA).  Glucocorticoid treatment also reduces acetylation of histone 
residues; however, the glucocorticoid receptor (GR) lacks deacetylase activity.  GR is known to 
interact with histone deacetylases (HDACs) and with corepressors that mediate gene 
transrepression.  In this investigation, GC induced histone deacetylation was demonstrated to be 
due to GR recruitment of HDAC1 and the corepressor complex SMRT.  These data show that 
reduced acetylation of immune functional genes associated with NKCA is likely due to histone 
deacetylation by HDAC1 and transrepression of those genes by SMRT. 
.  
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CHAPTER ONE 
INTRODUCTION 
Diagnosis of breast cancer increases emotional distress1,2.  Such psychological stress is 
associated with immune dysregulation1,3,4; in particular reductions in natural killer cell function are 
observed3.  Psychological stress activates the hypothalamic-pituitary-adrenal axis (HPA), resulting 
in the secretion of glucocorticoids (GCs).  Glucocorticoids, including cortisol, suppress immune 
function5,6.   
Glucocorticoids enter the cell, bind to the glucocorticoid receptor (GR) in the cytoplasm, 
and the GR-GC complex translocates into the nucleus.  Within the nucleus, GR inhibits 
transcription, which results in repression of associated genes7,8.  GC treatment of a natural killer 
(NK) cell line (NK-92) corresponds with decreased global histone acetylation of residues H4-K8 
and H4-K12, as well as reduced interferon-γ and perforin levels and NK cell activity (NKCA)9.  The 
molecular mechanism by which glucocorticoid treatment results in histone deacetylation is 
unknown.   
GC treatment is associated with deacetylation of lysine residues on histone proteins; yet, 
GR lacks deacetylase activity10.  GR is known to bind nuclear corepressor complexes that recruit 
histone deacetylases (HDACs) 10.  Therefore, it was hypothesized that GC treatment-induced 
histone deacetylation is due to GR recruitment of HDACs via corepressor complexes.  This study
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 used a NK-like cell line (YT-Indy) and a synthetic glucocorticoid analog (Dexamethasone) 
to model the effect of GCs have on NK cells, in order to determine whether glucocorticoid receptor 
recruits HDACs as well as corepressor molecules, and if this reduces NK cell activity. 
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CHAPTER TWO 
REVIEW OF LITERATURE 
2.1 Breast Cancer and Psychological Response 
Breast cancer is the second leading cause of death in American women11.  Women 
diagnosed with breast cancer report heightened stress perception, anxiety, fear, uncertainty, and 
mood disturbance12-18.  Psychological distress activates neuroendocrine pathways that increase 
levels of cortisol19,20, which impact immune function6.   
2.2 Stress and the Hypothalamic-Pituitary-Adrenal Axis 
Perceived stress activates the hypothalamic-pituitary-adrenal (HPA) axis (as depicted in 
figure 1), which leads to an increase in secretion of cortisol.  The hypothalamus releases 
corticotrophin-releasing hormone (CRH), which stimulates the pituitary to releases 
adrenocorticotropic hormone (ACTH).  Within the adrenal gland, ACTH induces the synthesis and 
secretion of cortisol.  Acute stress activates the HPA axis, elevating the levels of cortisol.  Acute 
stress initially activates HPA and, as the stressor persists, HPA activation diminishes and cortisol 
levels decline21-25.  Cortisol is elevated in women at breast cancer diagnosis1,4. 
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Hypothalamic-Pituitary-Adrenal Axis 
 
 
 
 
From: Eisen, 2011. 
Figure 1.  The HPA axis.  Perceived stress activates the hypothalamus to release corticotrophin-releasing hormone 
(CRH).  CRH induces the pituitary gland to release adrenocorticotropic hormone (ACTH), which stimulates the adrenal 
gland to produce cortisol.  Upon entry into the blood, cortisol encounters blood cells, including immune cells. 
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2.3 Glucocorticoids  
Glucocorticoids (GCs) regulate a variety of physiological functions, in addition to maintaining 
stress-related homeostasis27.  Glucocorticoids are also widely prescribed as therapeutic treatments 
for inflammation, autoimmunity, and lymphoproliferative disorders28; however, long-term use is 
associated with various side effects and GC resistance.  Cortisol, the most abundant glucocorticoid 
in humans, is produced by the adrenal gland; it is transported through the blood bound to 
corticosteroid-binding globulin (CBG) and albumin29.  Cortisol, like other steroid-derived lipophillic 
ligands, diffuses through the cell membrane into the cytoplasm, where it binds and activates its 
cognate receptor30. 
2.4 Glucocorticoid Receptor 
A.  Gene expression 
Glucocorticoid receptor (GR) is a member of the nuclear receptor super family, and is 
encoded by the gene nr3c1 on human chromosome 5 (region 5q31p).  The human GR (hGR) gene 
consists of nine exons; alternative splicing of exon 9 results in two highly homologous protein 
forms, α and β.  The hGRα functions as a ligand-dependent transcription factor when activated, 
and is expressed in most tissues.  The hGRβ does not bind glucocorticoid agonists, and is not as 
ubiquitously expressed as hGRα; hGRβ acts as a dominant-negative, suppressing GRα’s activity10.  
In addition to alternative splicing, multiple isoforms of hGRα are created by using the 8 alternative 
translation initiation sites; nr3c1 has three different promoters as well. 
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Glucocorticoid Receptor Domains 
 
 
 
 
From: Nicolaides, et al., 2010. 
Figure 2.  The structure of the human glucocorticoid receptor gene (nr3c1).  hGR consists of 9 exons; alternative 
splicing of exon 9 results in two isoforms, hGRα and hGRβ.  The N-terminal domain (NTD), depicted in light blue, 
contains the major transactivation domain.  Adjacent to the NTD, the DNA-binding domain (DBD) contains sequences 
for binding to GREs, dimerization, and nuclear translocation; it is shown in green.  The hinge region (HR) is between 
the DBD and the ligand-binding domain (LBD), which is the site of glucocorticoid binding. 
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B.  Protein domains (figure 2) 
GR’s N-terminal domain (NTD) contains the major transactivation domain, known as 
activation function (AF)-1, which is ligand-independent. This domain is involved in initiation of 
transcription.  GR’s DNA-binding domain (DBD) is located adjacent to the NTD; it has two zinc 
finger motifs that bind to specific DNA sequences known as glucocorticoid response elements 
(GREs).  The DBD also contains sequences important for receptor dimerization and nuclear 
translocation.  The hinge region is between the DBD and the ligand-binding domain (LBD), which 
forms the C-terminus of GR.  The LBD binds glucocorticoids and plays a critical role in ligand-
induced activation of the receptor.  The LBD also contains a second transactivation domain (AF-2), 
which is ligand-dependent, and is involved in dimerization, nuclear translocation, binding to heat 
shock proteins, and interaction with coactivators10.  Most of the variability between isoforms is 
present in the NTD or CTD; the DBD remains constant10. 
C.  Activation and Activity  
In the unactivated state, hGR exists predominantly within the cytoplasm, bound to a 
multimeric molecular chaperone complex, which includes heat shock proteins (HSPs) 90, 70, and 
50, and immunophilins.  HSP90 regulates ligand binding, retains GR in the cytoplasm, and masks 
GR’s two nuclear localization sequences (NLS); NL1 and NL2, which are adjacent to the DBD and 
in the LBD, respectively.   Upon binding ligand (glucocorticoids), GR undergoes conformational 
changes that releases it from chaperone proteins and reveal GR’s NLS, inducing rapid transit into 
the nucleus.  Although uninduced GR is predominantly cytoplasmic and activated GR is 
8 
 
 
 
predominantly nuclear, both activated and unactivated GR forms have been shown to shuttle 
between the nucleus and cytoplasm depending on both the NLS and the nuclear retention signal 
(NRS)10. 
Once in the nucleus, the activated GR-corticosteroid complexes can homodimerize via 
their zinc finger DBDs, and bind to GREs in promoter regions of corticosteroid-responsive genes 
(figure 3).  GR binding to GREs increases gene transcription via cis-activation31.  However, 
negative GRE sites, in which GR binds a GRE and, through cis-repression, suppresses gene 
transcription, have also been identified32. 
In addition to interaction with DNA directly, activated GR is also known to interact with 
other transcription factors through protein-protein interactions.   Many inflammatory genes lack 
GRE sites, but are transcriptionally repressed by glucocorticoids33.  The anti-inflammatory effects 
of GCs are mediated through trans repression (figure 3), as GR interacts and interferes with the 
transcription factors AP-1 and NF-κB34,32.  GCs inhibit histone H4K8 and K12 acetylation by 
reducing the histone acetyltransferase (HAT) activity of cyclic AMP response element binding 
protein (CBP).  Additionally, GC administration can increase histone deacetylase 2 (HDAC2) 
expression and target HDAC2 to NF-κB CBP complexes, which is associated with halted 
transcription of NF-κB-dependent genes35-37. 
D.  Regulation 
The glucocorticoid receptor is regulated at multiple levels.  First, basal expression of GR 
mRNA is controlled by the transcription factors c-Myb and Ets38.  However, glucocorticoids  
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GR Signal Transduction Pathway 
 
 
From Gross and Cidlowski, 2008. 
Figure 3.  Activation and activity of GR.  Cortisol enters the cell, dissociates GR from its chaperone protein complex, 
and induces translocation into the nucleus.  Within the nucleus, GR dimers bind to DNA directly at GREs; this cis 
regulation can either upregulate or downregulate gene expression.  GR can also interact with transcription factors 
through protein-protein interactions to up- or down-regulate transcription in trans.  In the case of STAT proteins, STAT-
5 as an example (d), GR interacts with DNA-bound STAT proteins to coactivate transcription from the STAT response 
element. 
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negatively regulate GR mRNA expression, as GR’s promoter contains a negative glucocorticoid 
response element (nGRE), to which liganded GR binds and represses transcription.  GR’s 
promoter has NF-κB, AP-1, and CREB regulatory motifs, which are sites for binding of these 
transcription factors that positively regulate GR transcription.  Liganded GR is known to repress the 
transcriptional activity of NF-κB and AP-1 by preventing interaction with transcription factors, 
coactivators or the DNA, itself37.  In addition to transcriptional regulation, GR undergoes several 
post-translational modifications, including phosphorylation, acetylation, sumoylation, and 
ubiquitination before and after ligand binding.  These modifications can influence subcellular 
trafficking, cofactor interaction, transcriptional activation, receptor stability, and turnover30. 
 Unactivated GR predominantly exists within the cytoplasm, while activated GR is mostly 
nuclear.  Constitutive shuttling between these compartments occurs for both the activated and 
inactive forms of GR40.  GR’s subcellular location at any given time is determined by the 
accessibility of GR’s two NLSs to nuclear import protein41,42, the availability and accessibility of 
nuclear export proteins43, and the exposure of GR’s nuclear retention signal (NRS)44. 
In addition to regulating expression and localization, exposure to glucocortcoids decreases 
the level of GR by degradation through the proteasome-ubiquitin pathway45. 
2.5 Histone Deacetylases 
Histone deacetylases (HDACs) are enzymes that remove acetyl groups from the ε-amino 
group of lysines on the N-terminal tails of histone proteins.  In general, increased levels of histone 
acetylation (hyperacetylation) are associated with increased transcription, while decreased 
acetylation (hypoacetylation) is associated with transcriptional repression.  Currently, eighteen 
HDACs have been identified; they are divided into four classes based on their homology with yeast 
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orthologs.  All HDACs, except class III, contain a conserved catalytic domain that uses a charge 
relay system to remove acetyl groups from target lysine residues; Zn2+ ion must be present within 
the zinc binding site of the catalytic pocket during the reaction.  HDACs also deacetylate other 
cellular proteins, including p53, E2F, α-tubulin, and MyoD46,47.   
A.  Class I HDACs 
Class I HDACs include HDAC 1, 2, 3, and 8, which contain a well-conserved catalytic 
domain and are related to the S. cerevisiae HDAC Rpd3.  The catalytic domain of Class I HDACs 
is located at the N-terminus, and comprises the majority of the protein48.  The distinguishing 
features of class I HDACs are the C-terminal domains, which are more divergent49.   
HDACs 1 and 2 are most closely related, having 82% sequence homology, while HDACs 3 
and 8 are most closely related to each other, sharing 34% homology. HDACs 1, 2, and 3 are 
known to associate with multiprotein complexes.  Both HDAC 1 and 2 are only active when 
complexed with mSin3A, nucleosome remodeling and histone deacetylation (NURD), or 
corepressor for RE1 silencing transcription factor (CoREST) corepressor complexes; silencing 
mediator of retinoic acid and thyroid hormone (SMRT) and nuclear receptor corepressor (NCoR) 
complexes are required for HDAC3’s activity50, although HDACs 1 and 2 are also known to 
associate with both SMRT and NCoR51-55. Additionally, both HDAC1 and HDAC2 have been shown 
to be recruited by GR56,35.  Like other class I HDACs, HDAC8 is ubiquitously expressed; however, 
HDAC8’s activity has been mostly limited to smooth muscle57. 
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 HDACs 1 and 2 are predominantly located in the nucleus, while HDAC3 is found in the 
nucleus, the cytoplasm, and is sometimes associated with the plasma membrane58.  Class I 
HDACs contain an NLS; however, only HDAC3 has a nuclear export signal (NES)59.  HDAC1 
requires a shuttle protein for nuclear export. 
B.  Classes II, III, and IV HDACs 
 Class II HDACs are evolutionarily related to class I HDACs, and have the same catalytic 
activity.  Class II is homologous to yeast protein HDA1.  While class I is ubiquitously expressed in 
most tissues, class II HDAC are expressed mostly in heart, brain, lung, spleen, kidney and smooth 
muscle59.  Although class II HDACs can associate with protein complexes, such an association is 
not required for enzymatic activity.  Class II HDACs are also stimulated to shuttle between the 
cytoplasm and nucleus60; this activity is often regulated by phosphorylation status of the HDACs. 
 Class III HDACs are evolutionarily unrelated to any other class of HDACs; they catalyze 
the transfer of acetyl groups to NAD, which is a required cofactor for class III activity.  The 
difference in catalytic activity protects class III HDACs from the effect of HDAC inhibitors, e.g. TSA 
and vorinostatin.  Class III HDACs are known as sirtuins, as they share homology with yeast Sir2.  
Sirt1 and Sirt2 shuttle between the nucleus and cytoplasm83.  Sirt6 and Sirt7 are found in the 
nucleus, and Sirt3, -4, and -5 are found in mitochondria83.  Class III HDACs are expressed in brain, 
heart, kidney, liver, pancreas, spleen, adipose, skeletal muscle, and nervous system tissues83. 
 Class IV HDACs, of which HDAC11 is the only member, are phylogenetically unrelated to 
class I or class II, yet share sequence homology within the catalytic site with classes I and II61.  
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HDAC11 shuttles between the nucleus and cytoplasm, and is expressed only in certain tissues, 
including the heart, brain, kidneys, and skeletal muscle62.  HDAC11’s regulatory role is still 
undetermined.   
2.6 Coregulator Complexes 
 Gene regulation is controlled in a number of ways, one of which is by enzymatic 
complexes that are known as coactivators and corepressors.  These “sense” and integrate cellular 
signals and can mediate chromatin modifications that impact transcription.  Coregulator complexes 
are composed of many subunits, and can be divided into two generic classes based on enzymatic 
activity: those that are capable of modifying histone tails and those that are ATP-dependent and 
serve to remodel chromatin.  The latter group presumably acts by modifying the interface between 
histone proteins and DNA itself; this activity results in nucleosomal sliding63.  Enzymes capable of 
covalently modifying histone tails include HDACs, histone acetyltransferases (HATs), 
methyltransferases, demethylases, kinases, phosphatases, ubiquitinases, and SUMO ligases.   
A.  Corepressor Complexes 
 Corepressor complexes are composed of several factors that “act in a combinatorial 
manner to antagonize the actions of coactivator complexes . . . and by mediating covalent 
modifications . . . that serve as marks for recruitment of additional factors involved in transcriptional 
repression,” (Rosenfeld, 2006).  Corepressor complexes (figure 4) include the nuclear corepressor 
complex (NCoR), the silencing mediator of retinoid and thyroid hormone receptors (SMRT), the  
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NCoR and SMRT corepressor complexes 
 
 
                    
From Jepsen and Rosenfield, 2002. 
Figure 4.  Corepressor complexes that include NCoR and SMRT.  Each complex contains a core protein,either NCoR 
or SMRT.  Other proteins, including HDACs, and even other protein complexes, for example Sin3a, interact with the 
core protein to form a large corepressor complex.  The association of various components consolidates a variety 
repressive functions, including histone deacetylation, ATP-dependent chromatin remodeling activity, and DNA 
methylation, into a single complex. 
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sin3-sin associated protein complex (Sin3-SAP), the nucleosome remodeling and histone 
deacetylation complex (NURD), the NURD-related HDAC-complex, and the CoREST –HDAC  
complex.  These related complexes are composed of a core protein that has sites for interaction 
with various cofactors, which depend on the activation status of the cofactors.  Cell-signaling 
events also impact the composition of proteins in corepressor complexes64. 
B.  Nuclear Receptor Corepressor Complex and Silencing Mediator of Retinoid and Thyroid 
Hormone Receptors  
 NCoR and SMRT are two of the many nuclear corepressor proteins, which recruit 
multiprotein complexes with histone deacetylase activity.  This results in chromatin modification, 
preventing transcription.  As figure 5 depicts, both NCoR and SMRT are modular proteins that have 
at least three repressing domains (RDs) in their NTDs, and two interacting domains (IDs) in their 
CTDs.  The IDs mediate interaction with nuclear receptors; although the IDs of NCoR and SMRT 
share structural similarities, the amino acid sequences of IDs between proteins are only 23% to 
53% homologous.  These differences in sequence homology suggest that NCoR and SMRT 
interact with nuclear receptors differently, and may possibly determine recruitment specificity in that 
each corepressor has nuclear receptors66. Certain nuclear receptors are only able to interact with 
one of these corepressors, for example, the receptor RevErb only associates with NCoR67.  Other 
nuclear receptors are capable of interacting with either corepressor, but preferentially recruit one 
complex over others64.   
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The domain structure of NCoR and SMRT 
 
 
 
 
From: Cohen, et al., 2000. 
Figure 5.  The domain structure of NCoR and SMRT.  Three repression domains (in grey) are present in the N-
terminus of the protein.  HDACs can interact with NCoR or SMRT through sequences within and adjacent to the 
repression.  The interaction domains (in black) are located at the C-terminus; these allow for interaction with nuclear 
receptors and other transcription factors.  It is the interacting domains of NCoR and SMRT that are distinct, resulting in 
specific preferences for members of the nuclear receptor family. 
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2.7 The Epigenetic Code 
 Epigenetic regulation is mediated by covalent modifications that impact gene expression 
without altering the DNA sequence84.  These processes can result in heritable changes in gene 
expression or in stable, long-term alterations of the transcriptional potential of the cell, which may  
not be heritable.  DNA is wrapped around an octomeric protein complex, consisting of two of each 
of the histone proteins (H2A, H2B, H3, and H4).  The combination of 146 bps of DNA and histone 
proteins composes the nucleosome, the basic unit of chromatin.  Epigenetic changes include either 
DNA methylation, which affects the accessibility of DNA, or modifications of N-terminal tails of 
histone proteins that indirectly impact DNA accessibility due to compaction or relaxation of 
chromatin structure85,86,87 (figure 6).  Modifications of residues on histones include acetylation88, 
deimination89, methylation90, phosphorylation91, proline isomerization92, sumoylation93, and 
ubiquitination94.  Acetyl groups are added to lysine residues, neutralizing their positive charge, 
disrupting the interaction with DNA’s negative charge, and loosening the compaction of 
chromatin95.  Relaxing the chromatin structure increases its accessibility to transcription factors 
and, subsequently, gene expression.  Removal of acetyl groups results in condensation of 
chromatin, repressing gene expression95.   
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The epigenome, histone modifications, and transcription 
 
 
 
From Thiagalingam et al., 2003. 
Figure 6. Formation of heterochromatin and euchromatin.  Corepressor complexes, containing HDACs to remove 
acetyl groups and DNA methyltransferases (DMNT) to methylate lysines, modifying histone tails to form 
heterchromatin, whilch silences transcription.  Coactivator complexes, including histone acetyltransferases (HAT) 
acetyl lysines and DNA demethylases (DDM), which remove methyl groups, relax chromatin to allow for gene 
transcription. 
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2.8 Relevance to this work 
 As previously discussed, the emotional distress brought on by breast cancer diagnosis is 
known to result in immune dysregulation1-4, specifically reductions in NK cell activity3.  As 
psychosocial stress activates the HPA to release cortisol in vivo, the effects of a GC was modeled 
in vitro with the synthetic GC, dexamethasone.  Previous work from this laboratory has 
demonstrated that decreased NK cell activity was due to decreased expression of immune relevant 
genes, including perforin and interferon-γ9.  Reduced expression of those proteins was associated 
with reduced acetylation of histone residues within the promoter regions of those genes.  Reduced 
acetylation results in chromatin compaction and reduced accessibility of those promoter regions to 
transcriptional machinery95.  The specific molecules mediating histone deacetylation during 
glucocorticoid treatment are unknown. 
 Glucocorticoid treatment is known to activate the glucocorticoid receptor, which is a 
nuclear receptor known to impact transcription.  However, GR lacks deacetylase activity itself, but it 
is known to interact with many of the nuclear corepressor complexes, which recruit histone 
deacetylases.  Thus, this project will evaluate whether histone deacetylation during GC treatment is 
a result of GC-activated GR binding of a corepressor complex, NCoR or SMRT, which may recruit 
HDAC 1, 2, or 3. 
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CHAPTER THREE 
HYPOTHESIS AND AIM 
The immunosuppressive effects of glucocorticoids (GCs) are well documented5,6,69,70.  In 
particular, reductions in natural killer (NK) cell activity9,72,73 and reduced production of effector 
molecules, including perforin, and inflammatory cytokines, specifically IFN-γ and IL-69, result from 
GC treatment.  Diminished production of immune molecules is due to decreased transcription of 
the genes, which is caused by decreased acetylation of lysine residues on histone tails.  Removal 
of acetyl groups results in compaction of the chromatin structure creating promoters that are 
inaccessible to transcription factors95.  Although decreased histone acetylation is observed during 
GC treatment, the molecular mechanism by which glucocorticoids affect acetylation is unknown.  
However, acetylation status, transcript and protein levels of effector molecules and cytokines, as 
well as NK cell function are restored when GC-treated cells are exposed to a histone deacetylase 
(HDAC) inhibitor9.  Therefore, it is probable that glucocorticoids induce HDACs, which deacetylate 
histone tails. 
Glucocorticoids diffuse through the cell membrane, dissociate glucocorticoid receptor (GR) 
from its cytoplasmic chaperone proteins, and induce translocation of GR into the nucleus.  Within 
the nucleus, GR can activate or repress transcription through direct or indirect interactions with 
DNA.  GCs are known to suppress inflammatory gene expression, specifically those regulated by 
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NF-κB and AP-1.  Many inflammatory gene promoters lack glucocorticoid response elements33, 
suggesting that GR-mediated suppression occurs without GR binding to DNA.  GR is known to 
bind both NF-κB and AP-1 and inhibit transcription of NF-κB and AP-1-regulated inflammatory 
genes34,32.  The promoter regions of such genes have reduced histone acetylation during GC 
treatment9.  However, GR itself lacks deacetylase activity10.  GR is known to interact with nuclear 
corepressor complexes30, which recruit HDACs50.  Thus, it is hypothesized that the glucocorticoid 
receptor interacts with HDACs during glucocorticoid treatment.  It is probable that GR’s recruitment 
of HDACs mediates the deacetylation of histone tails that GCs are known to induce. 
The aim of this project was to determine if GR, when bound by GC, recruits HDACs.  To 
assess recruitment of HDACs by, a model system using a natural killer-like cell line (YT-Indy) and a 
synthetic glucocorticoid analogue (Dexamethasone) was employed.  Dexamethasone (Dex) has 
been demonstrated to both reduce acetylation of histone 4-lysine 8 (H4K8) residue (Krukowski, 
unpublished data; supplemental figure 1) and decrease the lytic activity of YT-Indy cells (Bush, 
unpublished data, figure 7).  Since Dex decreases NK cell activity and also reduces histone 
acetylation in the YT-Indy cell line, (which expresses both GR and HDACs,) this cell line was used 
to evaluate the interactions among GR and HDACs. 
There are eighteen HDACs, which are divided into four classes based on homology to 
yeast HDACs.  Class I HDACs, including HDACs 1, 2, 3, and 8, are ubiquitously expressed in most 
tissues; although the activity of HDAC8 may be restricted to smooth muscle cells57.  Additionally, 
class I HDACs are involved in epigenetic regulation, as transcriptional repressors61.  HDACs 1, 2, 
and 3 require activation by nuclear corepressor complexes50, including nuclear receptor 
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corepressor (NCoR) and silencing mediator of retinoid and thyroid hormone (SMRT).  Both NCoR 
and SMRT are known to repress genes regulated by NF-κB and AP-1, and are known to interact 
with nuclear receptors65.  Therefore, interactions between GR and HDACs 1, 2, and 3 were 
assessed, as well as interactions between GR and NCoR and SMRT to address this aim.   
YT-Indy cells were cultured in the presence or absence of Dex, and then subjected to co-
immunoprecipitation assays targeting GR, HDACs 1, 2, or 3, NCoR, or SMRT.  To determine if 
HDACs immunoprecipitated with GR, western blot analysis of co-immunoprecipitations was used.  
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CHAPTER FOUR 
MATERIALS AND METHODS 
4.1 Cell Lines 
YT-Indy, a natural killer-like cell line (from Christopher J. Froelich, M.D.  Northwestern 
University) is a subline of YT, which was originally established from a child with acute lymphoma 
and thymoma74.  YT cell lines are cytotoxic, respond to IL-2, but lack rearranged TCR-β genes.  
YT-Indy cells are capable of killing target cells upon stimulation of the CD28 receptor by its ligand 
CD80/CD86 on the target cells75.  Additionally, YT-Indy cells do not express killer inhibitory 
receptors (KIRs) or C-type lectins on the cell surface76.  YT-Indy cells are IL-2 independent, and 
proliferate continuously in vitro without conditioned media.   
K652, a human erthyleukemic-like cell line, was obtained from the American Type Culture 
Collection.  K652 cells are highly sensitive targets of in vitro NK cell cytotoxicity.   
4.2 Culture Conditions 
Both YT-Indy cells and K562 cells were maintained at 37°C in an atmosphere of 5% CO2 
in suspension cultures in 75 cm² tissue culture flasks (Corning Glass Works).  The YT-Indy cell line 
was cultured in media containing RPMI 1640 (Invitrogen) at 2.5 x 105 cells/ml supplemented with 
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12% fetal bovine serum low LPS (Sigma), 100 units/ml penicillin (Invitrogen), 100 μg/ml 
streptomycin (Invitrogen), 0.1mM non-essential amino acids (Invitrogen), 0.1mM 2-
mercaptoethanol (Invitrogen), and 2mM L-glutamine (Invitrogen).  The K562 cell line was cultured 
in K562 media, composed of RPMI 1640 at 2.5 x 105 cells/ml supplemented with 10% fetal bovine 
serum (FBS) low LPS, 100 units/ml penicillin, 100 μg/ml streptomycin, 0.1mM non-essential amino 
acids, 0.1mM 2-mercaptoethanol, and 2mM L-glutamine.   
4.3 Glucocorticoid Treatment 
Dexamethasone (Dex) (Sigma), a synthetic glucocorticoid analogue, was used to simulate 
cortisol.  YT Indy cells, cultured at 2.5 x 105 cells/ml, were treated in 75 cm² tissue culture flasks 
with 100nM (10-7M) Dex for 2, 4, 8, and 24 hours.  This concentration of Dex did not decrease cell 
viability and is a concentration demonstrated previously to differentially regulate dexamethasone 
responsive genes77.  After treatment with Dex, YT Indy cells were counted, and viability was 
assessed using 0.1% Trypan blue.  Cells were resuspended to 5 x 106 cells/ml in RPMI media 
lacking all supplements.   
4.4 Natural Killer Cell Activity 
A.  Preparation of Cells 
K562 tumor cells were radioactively labeled with 100 μCi of [51Cr] (New England Nuclear).  
K562 cells were incubated at 37°C with [51Cr] in a 10ml conical tube for 1 hour, briefly shaking 
every 15 minutes to prevent cells from pelleting.  After 1 hour incubation, cells were pelleted by 
centrifugation at 1,000 rpm for 3 minutes.  The supernatant containing radioactivity was removed 
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using a glass pipette and discarded.  The pelleted K562 cells were washed with 15 ml K562 media; 
cells were pelleted at 1,000 rpm for 10 minutes, and the wash media was discarded.  The washing 
and pelleting steps were repeated three times.  After washing, K562 cells were resuspended in 1 
ml K562 media; cell number and viability were assessed using 0.1% Trypan blue.  5 x 105 K562 
cells were added to 10 ml K562 media, (resulting in a final concentration of 5 x 104 cells/ml.)     
 Dex- and non-treated YT-Indy cells were collected from culture flasks in a 50ml conical 
tube, and pelleted at 1,000 rpm for 5 minutes.  Cells were washed with PBS, and pelleted at 1,000 
rpm for 5 minutes.  Cells were resuspended with YT-Indy media, and counted using 0.1% Trypan 
blue.  Cells were resuspended to a concentration of 5 x 106 cells/ml.   
B.  Natural Killer Cell Activity Assay 
YT -Indy cell lytic activity against tumor targets was assessed by chromium release assay 
as previously described1.  One-hundred μl radiolabeled K562s were plated in a 96-well plate 
(Fisher).  Dex- and non-treated YT-Indy cells were added to the wells to achieve effector to target 
ratios of 30:1, 20:1, and 10:1.  Additional K562 media was added to bring the final volume to 200 
μl/well.  Additionally, 6 wells of K562 cells were plated to determine the maximal and minimal 
radioactivity released by K562 cells.  The NKCA plate was incubated for 4 hours at 37°C.  After the 
incubation, supernatants were removed using a Skatron harvesting press and the associated 
radioactivity was determined.  Results are expressed as percent cytotoxicity, calculated as: % 
Cytotoxicity = [(experimental DPM) – (minimum DPM)] / [(maximum DPM) – (minimum DPM)] x 
100. 
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DMP is disintegrations per minute.  All experimental means were calculated from triplicate values.  
Lytic units (LU) were calculated using a program written by David Coggins, FCRC, Frederick, MD.  
LU represents the number of cells per 107 effectors required to achieve 20% lysis of the target 
cells.   
4.5  Nuclear and cytoplasmic separation 
Dex- and non-treated YT-Indy cells were harvested from culture flasks, and pelleted at 
1,000 rpm for 5 minutes.  Cells were counted using 0.1% Trypan blue, and resuspended to 5 x 106 
cells/ml in YT-Indy media lacking supplements.  Nuclear and cytoplasmic fractions of YT-Indy cells 
were separated using ProteoJET Cytoplasmic and Nuclear Protein Extraction Kit (Fermentas).  
Briefly, 1 ml of YT-Indy cells (5 x 106 cells) were placed in a microfuge tube; cells were pelleted 500 
x g for 5 minutes.  Pelleted cells were washed with 1 ml of phosphate buffered saline (PBS); cells 
were centrifuged 500 x g for 5 minutes, and supernatant was discarded.  The pelleted cells were 
resuspended by adding 200 μl of cell lysis buffer and vortexing the tube at low speed for 10 
seconds.  Tubes were incubated on ice for 8 minutes, and vortexing was repeated.  To separate 
the cytoplasm from the nuclear fraction, tubes were centrifuged at 500 x g for 7 minutes at 4°C.  
The supernatant, which contained the cytoplasmic contents, was removed without disturbing the 
pellet and placed in another microcentrifuge tube and put on ice.  The pelleted nuclei were 
resuspended by adding 500 μl nuclei wash buffer, and vortexing until pellet disappeared.  Tubes 
were incubated on ice for 2 minutes, and vortexing was repeated.  Tubes were centrifuged for 7 
minutes at 500 x g at 4°C.  This washing step was repeated once.  The pelleted nuclei were 
resuspended by adding 150 μl ice cold nuclei storage buffer to each tube. 
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4.5 Preparation of whole cells 
Dex- and non-treated YT-Indy cells were harvested from culture flasks, and pelleted at 
1,000 rpm for 5 minutes.  Cells were counted using 0.1% Trypan blue, and resuspended to 5 x 106 
cells/ml in YT-Indy media lacking supplements.  1 ml of YT-Indy cells (5 x 106 cells) was placed in a 
microfuge tube. 
4.6 Lysis of whole cells and nuclei 
Tubes containing whole cells and nuclei from the nuclear and cytoplasmic fraction steps 
were centrifuged for 5 minutes at 500 x g.  The supernatants were discarded, and the pellets were 
resuspended with 1 ml ice cold PBS.  Tubes were centrifuged for 5 minutes at 500 x g, and the 
supernatant was discarded.  The pellet was resuspended with 500 μl non-denaturing lysis buffer 
(20mM Tris HCl pH=8, 137 mM NaCl, 10% glycerol, 1 % Nonidet P-40, 2mM EDTA) and 2 μl of 
protease inhibitor cocktail.  Tubes were incubated for 30 minutes at 4°C with constant rotation 
using a GyroMini rotating platform (Dot Scientific).  Tubes were centrifuged for 10 minutes at 
10,000xg.  The supernatant was aspirated from the pellet, and placed into a new microcentrifuge 
tube. 
4.7 Co-immunoprecipitation 
A.  Lysate preclearing 
 To nuclear and whole cell lysates, 25 μl of Protein G magnetic beads (New England 
BioLabs) was added.  To tubes containing the cytoplasmic contents, 10 μl of Protein G magnetic 
beads was added.  Tubes were incubated for 1 hour at 4°C with constant rotation using a GyroMini 
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rotating platform.  The beads were collected by magnetic separation, and the supernatant placed 
into a new tube.  This step removes any cellular contents that would bind to the magnetic beads. 
B. Cross-linking antibody to magnetic beads 
The antibody used for immunoprecipitation was added to a tube containing borate buffer 
(0.2M boric acid, 50mM sodium tetraborate decahydrate, pH = 9.0).  The antibodies used for 
immunoprecipitation were specific for GR (AbCam ab3671), HDAC1 (Millipore 06-720), HDAC2 
(AbCam ab32117), HDAC3 (AbCam ab32369), NCoR (AbCam ab24552), SMRT (AbCam 
ab24551), and normal mouse IgG (Millipore 12-371).  The dilution factors (antibody:precleared 
lysate) used for each antibody were as follows: 1:20 for GR and HDAC1, 1:60 for HDAC2, and 1:50 
for HDAC3, NCoR, and SMRT.  The proper volume of antibody was added to the borate buffer to 
achieve the optimal dilution for the antibody and to arrive at a volume of 500 μl of antibody in 
borate buffer solution.  The optimal dilutions were determined by testing a series of experimental 
dilutions, selecting the dilution that gives the strongest positive reaction with minimum background. 
Fifty μl Protein G magnetic beads were placed into a microfuge tube.  The beads were 
collected by magnetic separation, and the supernatant was discarded, leaving enough liquid to 
cover the beads and prevent drying.  450μl of antibody in borate buffer was added to the tube 
containing the magnetic beads.  The tubes were incubated for 1 hour at room temperature with 
constant rotation using a GyroMini rotating platform.  The beads were collected by magnetic 
separation, and the supernatant was discarded.  The beads were resuspended with 500 μl of 
borate buffer, and incubated for 2 minutes at room temperature on a rotator platform.  The beads 
were collected by magnetic separation, and the supernatant was discarded.  The resuspension 
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with borate buffer was repeated once.  The beads were resuspended with 450 μl of borate buffer, 
and 2.5 mg of room temperature dimethyl pimelimidate (Sigma Aldrich) was added.  The tubes 
were incubated on a platform rotator for 30 minutes at room temperature.  The beads were 
collected by magnetic separation, and the supernatant was discarded.  The beads were 
resuspended with 500 μl of ethanolamine buffer (0.2M ethanolamine in PBS, pH = 8.0).  The tubes 
were incubated for 30 minutes at room temperature on a rotator platform.  The beads were 
collected by magnetic separation, and the supernatant was discarded.  The beads were 
resuspended with 500 μl of ethanolamine buffer, and incubated at room temperature on a rotator 
platform for 2 hours.  The beads were collected by magnetic separation, and the supernatant was 
discarded.  The beads were washed with 500 μl of phosphate buffered saline (PBS).  The beads 
were collected by magnetic separation, and the supernatant was discarded.  The beads were 
resuspended in 50 μl of PBS.   
C. Co-iImmunoprecipitation 
 Five-hundred μl of precleared whole cell, nuclei, or cytoplasmic lysates were added to 
tubes containing the cross-linked antibody and beads.  The tubes were gently vortexed, and 
incubated overnight at 4°C with constant rotation using a GyroMini rotating platform.  The beads 
were collected by magnetic separation, and the supernatant was discarded.  The pellet wash 
washed by resuspending with 500 μl of non-denaturing lysis buffer, and incubating on a rotator 
platform for 5 minutes at room temperature.  The washing steps were repeated twice. 
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4.8  Western Blot 
A.  Sample preparation 
 For analysis of subcellular localization, 100 μl of 4X Laemmli’s SDS (reducing) sample 
buffer (Boston BioProducts) was added to tubes containing either whole cell or nuclei lysates; 50 μl 
of 4X Laemmli’s SDS sample buffer was added to tubes containing cytoplasmic contents.  One-
hundred fifty μl of 4X Laemmli’s SDS sample buffer was added to tubes containing 
immunoprecipitates.  All tubes were boiled for 5 minutes.  Beads were collected by magnetic 
separation, the supernatants collected and placed in new microcentrifuge tubes.  All tubes were 
incubated at 4°C for 20 minutes with constant rotation using a GyroMini rotating platform, and then 
stored at -20°C. 
B. Gel electrophoresis and transfer 
 Equal volumes of samples were resolved on 8 – 10 % SDS PAGE gels under denaturing 
and reducing conditions.  A Multicolor Protein Ladder (Fermentas) and a Precision Plus Dual 
Standard (BioRad) were used a molecular weight standards.  After electrophoresis, proteins were 
transferred from gels to nitrocellulose membranes for 2.5 hours at 100 Volts. 
C.  Immunoblotting 
 Nitrocellulose membranes (BioRad) containing proteins were incubated in blocking buffer 
(5% milk in TBST) for 1 hour at room temperature on a rotator platform.  Blots were probed with 
primary antibodies specific for GR, HDACs 1, 2, and 3, NCoR, and SMRT; the same antibodies 
31 
 
 
 
used for co-immunoprecipitation were used for immunoblotting.  Antibodies were diluted in blocking 
buffer using the following dilutions (Ab:blocking buffer): 1:500 for GR, 1:1000 for HDACs 1, 2, and 
3, NCoR, and SMRT.  Blots were probed with primary antibodies overnight at 4°C with constant 
rotation using a GyroMini rotating platform.  Blots were washed three times with washing buffer (1X 
TBST) by incubating on a rotating platform for 5 minutes.  Blots were then probed with goat anti-
rabbit IgG HRP-conjugated antibody (Millipore 12-348) as a secondary.  Blots were washed four 
times with washing buffer by incubating on a rotating platform for 5 minutes.  
 Blots were visualized using Supersignal West Pico chemiluminescent reagents (Fisher), 
and were developed on blue biofilm (BioRad).   
D.  Quantification of Western Blot 
 Films of western blots were scanned to a computer, and blot density was quantified using 
Image J software.  Purity of nuclear and cytoplasmic fractions was determined by blotting for 
LaminB1 (AbCam ab16048), which is restricted to the nuclear envelope, and GAPDH (Cell 
Signaling 2118), which is localized to the cytosol.  Nuclear fractions were more than 90% pure, and 
cytoplasmic fractions were more than 85% pure.   
4.9 Statistical Analysis 
 For determination of subcellular localization of GR and HDACs 1, 2, and 3, three 
independent experiments were conducted.  Results are presented as mean ± standard error of the 
mean, with N = 3.  Quantitative data was analyzed by two-tailed, two sample, homoscedastic 
Student’s T-test.  Values with p < 0.05 were considered statistically significant. 
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4.10 Buffers and Solutions 
Phosphate Buffered Saline (PBS): 100 ml 10X PBS (Invitrogen) and 900 ml Millipore water 
Cell Lysis Buffer (per tube): 200 μl ProteoJET cell lysis buffer (Fermentas), 2 μl ProteoJET 0.1M 
DTT, and 2 μl protease inhibitor cocktail (Sigma Aldrich). 
Nuclei Wash Buffer (per tube): 1000 μl ProteoJET nuclei washing buffer, 30 μl 0.1M DTT, and 2 μl 
protease inhibitor cocktail. 
Nuclei Storage Buffer (per tube): 150 μl ProteoJET nuclei storage buffer, 7.5 μl 0.1M DTT, and 2 μl 
protease inhibitor cocktail. 
Non-denaturing Lysis Buffer (for 100ml): 4ml of 0.5M Tris-HCl, 2.75ml of 5M NaCl, 10ml glycerol, 
1ml NP-40, 400μl of 0.5M EDTA, and fill to 100 ml with Millipore water.  Each tube requires 500 μl 
of non-denaturing lysis buffer with 2 μl protease inhibitor cocktail added just prior to use. 
Borate Buffer (for 50 ml): dissolve 125 mg boric acid in 10 ml Millipore water and dissolve 765 mg 
in 40 ml Millipore water.  Mix the two solutions, and adjust the pH to 9.0. 
Ethanolamine Buffer (for 50 ml): 633.4 μl ethanolamine, fill to 50 ml with PBS, and adjust pH to 8.0 
with HCl.  
Ammonium Persulfate (APS): 1 g ammonium persulfate (Fisher) and 10 ml Millipore water. 
8% SDS-PAGE gel: 2.0 ml ProtoGel 30% (Fisher), 1.875 ml 4X Resolving Buffer (Fisher), 3.54 ml 
Millipore water, 75 μl APS, and 7.5 μl Temed (Fisher). 
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10% SDS-PAGE gel: 2.5 ml ProtoGel 30%, 1.875 ml 4X Resolving Buffer (Fisher), 3.04 ml 
Millipore water, 75 μl APS, and 7.5 μl Temed. 
Stacking gel: 260 μl ProtoGel 30%, 500 μl Stacking Buffer (Fisher), 1.22 ml Millipore water,10 μl 
APS, and 2 μl Temed. 
1X TBST (for 1 L): 100 ml 10X TBST (Boston BioProducts) and 900 ml Millipore water. 
5% Milk Blocking Solution (for 50 ml): 2.5 g powdered milk and fill to 50 ml with 1X TBST. 
Western Blot Washing Buffer: 1X TBST solution 
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CHAPTER FIVE 
RESULTS 
5.1  Comparative analysis of natural killer cell activity (NKCA) of the YT-Indy cell line with and 
without dexamethasone treatment 
The ability of dexamethasone (Dex) to affect YT-Indy lytic activity was evaluated using a standard 
chromium release assay.  YT-Indy cells were treated with dexamethasone (10-7M) for 4, 8, 12, or 24 hours.  
This concentration of Dex was previously determined to be optimal9.  Dex- and non-treated YT-Indy cells 
were then incubated for 4 hours with Cr51-labeled cancer cell line K562 at effector to target ratios of 10 to 1, 
20 to 1, and 30 to 1.  Supernatants containing radioactivity released by the cancer cells was collected, and 
the radioactivity was determined.  The results are presented in figure 7.   
At the 4 hour time point, lytic activity of YT-Indy cells was reduced from 54.33 lytic units (LU) to 
43.10 LU with dexamethasone treatment.  Lytic activity was reduced from 66.40 LU to 33.74 LU with 8 
hours of Dex treatment.  With 12 hours of Dex treatment, a reduction in lytic activity from 68.77 LU to 20.47 
LU was observed.  At the 24 hour time point, Dex treatment reduced lytic activity from 50.59 LU to 12.08 LU.  
The greatest reduction in lytic activity occurred with 24 hours of dexamethasone treatment, but decreased 
lytic activity was observed with as little as 4 hours of dexamethasone treatment.  Dex treatment had no 
effect on the viability of the YT-Indy cell line.  While decreased lytic activity was observed at all time points 
tested, statistical difference (p < 0.05) between non-treated and Dex-treated cells was observed at 8, 12, 
and 24-hour time points.  Overall, the data demonstrate that dexamethasone decreases lytic activity of YT-
Indy cells in a time-dependent manner. 
35 
 
 
 
 
 
 
NKCA 
 
 
 
Figure 7.  NKCA assay results.  (n = 3) Each bar represents the lytic units associated with each treatment condition.  
Each condition was performed in triplicate.  Untreated YT-Indy cells are represented by black bars, and 
dexamethasone-treated cells are represented by grey bars.  The data were analyzed using a student’s t-test to 
calculate the probability of a significant difference between the non-treated and Dex-treated conditions.  The * denotes 
statistical difference (p < 0.05) in lytic activity between untreated and Dex-treated cells.  Statistically significant 
decreases in lytic activity due to dexamethasone were observed for treatment durations of 8 hours (p = 0.0002), 12 
hours (p = 0.00008), and 24 hours (p = 0.00003).  Values are presented as means +/- SEM. 
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5.2 Comparative analysis of the subcellular localization of glucocorticoid receptor (GR) during 
dexamethasone treatment 
Subcellular localization of GR was assessed in nuclear and cytoplasmic fractions extracted from 
dexamethasone-treated and non-treated YT-Indy cells.  The presence of GR within nuclear and cytoplasmic 
fractions was determined by Western analysis, using an antibody specific for glucocorticoid receptor.  A 
representative immunoblot from an SDS-PAGE gel is shown in figure 8 A.  The density of the protein bands 
appearing on film was quantified using ImageJ software.  The total level of GR within the cell was calculated 
from the average level GR within the nucleus and the cytoplasm.  Figure 8 B displays the percentage of the 
total cellular GR that is present in either fraction at each time point.   
Glucocorticoid receptor is 97 kDaltons.  In non-treated YT-Indy cells, GR is found in both the 
cytoplasm (figure 8 A, lane 2) and the nucleus (lane 1), with the majority present in the cytoplasm (74%, as 
indicated in figure 8 B).  Dexamethasone induces a shift in the proportion of total cellular glucocorticoid 
receptor found in the nucleus.  With 2 hours of Dex treatment, a small increase in the percentage of GR 
within the nucleus (from 26% in non-treated cells to 34% with 2 hours of Dex) is observed.  The greatest 
increase in GR found within the nucleus occurs at 4 hours of Dex treatment, when 69% of all GR within the 
cell exists in the nucleus.  The change in the levels of GR within the nucleus at 4 hours as compared to 
untreated cells is statistically significant (p = 0.0142).  At the 8 hour time point, GR localization returns to 
levels similar to that of untreated cells, with only 30% of total GR present in the nucleus.  Dexamethasone 
induces a shift in glucocorticoid receptor location to favor nuclear localization at 4 hours of treatment.  With 
24 hours of treatment, GR is found in approximately equal levels (data not shown). 
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Subcellular Localization of GR 
 
 
 
 
 
 
 
 
 
Figure 8.  Subcellular localization of GR.  A.  Representative western blot with non-treated nuclear fraction (lane 1), 
non-treated cytoplasmic fraction (lane 2), nucleus from 2-hour Dex treatment (lane 3), cytoplasm from 2-hour Dex 
treatment (lane 4), nucleus from 4-hour Dex treatment (lane 5), cytoplasm from 4-hour Dex treatment (lane 6), nucleus 
from 8-hour Dex treatment (lane 7), and cytoplasm from 8-hour Dex treatment (lane 8) probed for GR.  GR is 97kDa; 
blot is marked at 95kDa.  B.  Blot density quantified using ImageJ software.  (n = 3)  Each bar represents the percent of 
total GR within the cell that is present in either the nucleus or cytoplasm.  Nuclear fractions are represented by black 
bars; cytoplasmic fractions are represented by grey bars.  In non-treated cells, 74% of the total GR is present in the 
cytoplasm.  The largest increase in GR found in the nucleus occurs with 4 hours of Dex treatment; the * denotes 
statistical difference (p < 0.05) in the level of GR in nucleus between 4 hour treatment and non-treated cells.  Values 
are presented as means +/- SEM.  
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5.3 Comparative analysis of subcellular localization of HDACs 1, 2, and 3 during dexamethasone 
treatment 
 Subcellular localization of HDACs 1, 2, and 3 was also assessed using nuclear and cytoplasmic 
extracts from YT-Indy cells treated for 0, 2, 4, and 8 hours with dexamethasone.  The location of HDACs in 
nuclear or cytoplasmic fractions was determined by immunoblotting with antibodies specific for HDAC1, 
HDAC2, and HDAC3.  Each time point was performed in triplicate.  The density of protein bands appearing 
on film was quantified using ImageJ software.  The total cellular level of each HDAC was calculated as the 
sum of the nuclear and cytoplasmic levels. 
A.  HDAC1 
Figure 9 A is a best example western blot of HDAC1.  Lanes 1 and 2 display HDAC1 in the nucleus and 
cytoplasm, respectively, of untreated cells, while lanes 3 – 8 are from Dex-treated cells.  HDAC1 is a 65 kDa 
protein that is present in both cellular fractions of YT-Indy cells, regardless of dexamethasone treatment.  
Figure 9 B is more representative of the data, as it presents the average proportion of HDAC1 in the 
subcellular compartments.  In untreated cells, 56% of total cellular HDAC1 is nuclear.  On average, 
dexamethasone increases the proportion of HDAC1 present in the nucleus with 2 and 4 hour treatments; at 
2 hours, 76% of HDAC1 is in the nucleus, and 70% is nuclear at 4 hours (figure 9 B).  The increase in 
nuclear HDAC1 observed with 2 hours of Dex treatment is statistically significant (p = 0.0107).  
Dexamethasone induces HDAC1 to favor nuclear localization with 2 and 4 hours of treatment.  However, at 
8 hours of treatment, HDAC1 is found in equal proportions in either compartment, a distribution similar to 
untreated cells.   
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Subcellular localization of HDAC1 
 
 
 
 
 
 
 
 
 
Figure 9.  Subcellular localization of HDAC1.  A.  Representative western blot with non-treated nuclear fraction (lane 
1), non-treated cytoplasmic fraction (lane 2), nucleus from 2-hour Dex treatment (lane 3), cytoplasm from 2-hour Dex 
treatment (lane 4), nucleus from 4-hour Dex treatment (lane 5), cytoplasm from 4-hour Dex treatment (lane 6), nucleus 
from 8-hour Dex treatment (lane 7), and cytoplasm from 8-hour Dex treatment probed for HDAC1.  HDAC1 is 65kDa; 
blot is marked at 72kDa.  B.  Blot density quantified using ImageJ software.  (n = 3)  Each bar represents the percent of 
total HDAC1 within the cell that is present in either the nucleus or cytoplasm.  Nuclear fractions are represented by 
black bars; cytoplasmic fractions are represented by grey bars.  The * denotes statistical difference (p < 0.05) in the 
level of GR in nucleus between 2 hour treatment and non-treated cells.  Values are presented as means +/- SEM.  
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B. HDAC2 
HDAC2’s best representative western blot is depicted in figure 10 A.  HDAC2 is a 55 kDa protein 
that is present in both nuclear (lane 1) and cytoplasmic (lane 2) fractions of untreated YT-Indy cells, as well 
as the nucleus (lanes 3, 5, and 7) and cytoplasm (lanes 4, 6, and 8) of Dex-treated cells.  Figure 10 B is 
more representative of the data, as it is the average of quantified levels of GR.  On average, HDAC2 is 
divided almost equally between the nucleus and cytoplasm in YT-Indy cells (figure 10 B); 52% of all HDAC2 
in the cell is nuclear.  Dexamethasone initially induces a statistically significant (p = 0.033) increase in the 
proportion of HDAC2 in the nucleus at 2 hours, with 71% of HDAC2 found in the nucleus.  However, 
continued Dex treatment finds the HDAC2 divided almost equally between the nucleus (47%) and cytoplasm 
(53%) at 4 hours, and increasing the cytoplasmic proportion (to 58%) at 8 hours.   
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Subcellular localization of HDAC2 
 
 
 
 
 
 
 
 
 
Figure 10.  Subcellular localization of HDAC2.  A.  Representative western blot with non-treated nuclear fraction (lane 
1), non-treated cytoplasmic fraction (lane 2), nucleus from 2-hour Dex treatment (lane 3), cytoplasm from 2-hour Dex 
treatment (lane 4), nucleus from 4-hour Dex treatment (lane 5), cytoplasm from 4-hour Dex treatment (lane 6), nucleus 
from 8-hour Dex treatment (lane 7), and cytoplasm from 8-hour Dex treatment probed for HDAC2.  HDAC2 is 55kDa; 
blot is marked at 52kDa.  B.  Blot density quantified using ImageJ software.  (n = 3)  Each bar represents the percent of 
total HDAC2 within the cell that is present in either the nucleus or cytoplasm.  Nuclear fractions are represented by 
black bars; cytoplasmic fractions are represented by grey bars.  The * denotes statistical difference (p < 0.05) in the 
level of GR in nucleus between 2 hour treatment and non-treated cells.  Values are presented as means +/- SEM.  
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C.  HDAC3 
Figure 11 A is a best example western blot for HDAC3.  Lanes 1 and 2 display HDAC3 in the 
nucleus and cytoplasm, respectively, of untreated cells, while lanes 3 – 8 are from Dex-treated cells.  
HDAC3 is a 49 kDa protein that, like HDACs 1 and 2, is present in both the nucleus and cytoplasm 
of both untreated and Dex-treated cells.  Figure 11 B is more representative of the data, as it presents 
the average proportion of GR in the subcellular compartments.  In general, dexamethasone treatment 
had little effect on subcellular localization of HDAC3.  In untreated cells, 64% of total cellular 
HDAC3 is in the nucleus.  Similarly, 57% to 66% of total HDAC3 is within the nucleus of cells 
treated with dexamethasone.  This trend is displayed in the representative blot (figure11 A) as well.  
Therefore, dexamethasone treatment does not impact the subcellular localization of HDAC3.   
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Subcellular localization of HDAC3 
 
 
 
 
 
 
 
 
 
Figure 11.  Subcellular localization of HDAC3.  A.  Representative western blot with non-treated nuclear fraction (lane 
1), non-treated cytoplasmic fraction (lane 2), nucleus from 2-hour Dex treatment (lane 3), cytoplasm from 2-hour Dex 
treatment (lane 4), nucleus from 4-hour Dex treatment (lane 5), cytoplasm from 4-hour Dex treatment (lane 6), nucleus 
from 8-hour Dex treatment (lane 7), and cytoplasm from 8-hour Dex treatment probed for HDAC3.  HDAC3 is 49 kDa; 
blot is marked at 50 kDa.  B.  Blot density quantified using ImageJ software.  (n = 3)  Each bar represents the percent 
of total HDAC3 within the cell that is present in either the nucleus or cytoplasm.  Nuclear fractions are represented by 
black bars; cytoplasmic fractions are represented by grey bars. Dexamethasone treatment does not induce a 
statistically significant change in subcellular localization of HDAC3.   Values are presented as means +/- SEM.  
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5.4 Interactions between GR, HDACs, and Corepressor Complexes 
 Interaction between proteins was assessed by co-immunoprecipitation assays.  YT-Indy 
cells were cultured with dexamethasone for 4 hours.  Whole cells were lysed using non-denaturing 
lysis buffer to maintain protein-protein interactions; thus, proteins bound together at the time of 
lysis immunoprecipitate together.  Lysates were probed with antibodies specific for glucocorticoid 
receptor and HDACs 1, 2, and 3; antibodies specific for the corepressor complexes NCoR and 
SMRT were also used to immunoprecipitate.  Lysates were also probed with an IgG antibody that 
is not specific for any cellular proteins as a negative control; this ensures that immunoprecipitated 
proteins are not interacting with IgG antibodies non-specifically.  Immunoprecipitates were 
examined by SDS-PAGE gel, and immunoblotted for GR, NCoR, SMRT, and HDACs 1, 2, and 3.  
Figure 12 shows that the IgG antibody (lane 1) does not immunoprecipitate GR, SMRT, NCoR, 
HDAC1, HDAC2, or HDAC3.  Glucocorticoid receptor is present when an antibody specific for GR 
immunoprecipitates protein (lane 2).  Additionally, GR immunoprecipitates with SMRT and HDAC1, 
but not NCoR, HDAC2, or HDAC3.  The antibody specific for SMRT pulls down SMRT, as well as 
GR and HDAC1 (lane 3).  NCoR is the only protein present when lysates were probed with an 
NCoR-specific antibody (lane 4).  The HDAC1-specific antibody immunoprecipitates GR with 
HDAC1 (lane 5).  Only HDAC2 is pulled down by the HDAC2-specific antibody (lane 6).  HDAC3 is 
the only protein present when lysates were probed with an antibody for HDAC3 (lane 7).  GR and 
SMRT immunoprecipitate together, whether a GR-specific antibody or a SMRT-specific antibody is 
used.  HDAC1 and GR also immunoprecipitate together, whether a GR-specific or HDAC1-specific    
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Co-immunoprecipitation of Whole Cell Lysates 
 
 
 
   
    
    
    
    
   
 
 
Figure 12.  Interaction between GR, corepressor complexes, and HDACs.  YT-Indy cells treated with Dexamethasone 
for 4 hours.  Cell lysates were immunoprecipitated with antibodies specific for GR (lane 2), SMRT (lane 3), NCoR (lane 
4), HDAC1 (lane 5), HDAC2 (lane 6), and HDAC3 (lane 7); as a negative control, lysates were immunoprecipitated with 
IgG antibody (lane 1).  This is a best representative western blot.  No bands appear in lysates immunoprecipitated with 
IgG (lane 1). SMRT and HDAC1 immunoprecipitate with GR.  GR and HDAC1 immunoprecipitate with SMRT (lane 3).  
GR immunoprecipitates with HDAC1 (lane 5).  NCoR Ab only immunoprecipitates NCoR (lane 4), HDAC2 Ab 
immunoprecipitates only HDAC2 (lane 5), and HDAC3 Ab only pulls down HDAC3 (lane 7).   
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antibody was used.  While a SMRT-specific antibody is capable of immunoprecipitating HDAC1, an 
HDAC1-specific antibody does not immunoprecipitate SMRT.   
 As sections 5.2 and 5.3 presented, GR and HDAC1 are present in both the nucleus and 
cytoplasm of YT-Indy cells.  Therefore, to ensure the interaction found in lysates of whole cells 
were capable of mediating decreases in histone acetylation observed during dexamethasone 
treatment (supplemental figure 1), the co-immunoprecipitation assay was repeated with nuclear 
fractions extracted from YT-Indy cells.  Nuclei were extracted as previously described (see section 
4.5).  Nuclei were lysed using the same non-denaturing lysis buffer as whole cells to ensure the 
preservation of protein-protein interactions.  Nuclear lysates were probed with a non-specific IgG 
antibody as a negative control, as well as antibodies specific for GR, SMRT, and HDAC1, as those 
proteins were shown to interact in whole cells.  Figure 13 demonstrates that no proteins were 
pulled down with the non-specific IgG antibody (lane 1).  Similar to whole cell lysates, the GR-
specific antibody pulled down GR, SMRT, and HDAC1 (lane 2) in nuclear lysates.  Both GR and 
HDAC1 were immunoprecipitated with SMRT (lane 3), and HDAC1 immunoprecipitated both GR 
and SMRT (lane 4).  Co-immunoprecipitations of proteins found in nuclear extracts confirmed that 
GR interacts with SMRT and HDAC1, and suggests that GR is recruiting the corepressor SMRT, 
as well HDAC1 during dexamethasone treatment to mediate the deacetylation of histone proteins.    
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Co-immunoprecipitation of Nuclear Lysates 
 
 
 
 
 
 
 
 
Figure 13.  Interaction among GR, SMRT, and HDAC1.  YT-Indy cells were treated with dexamethasone for 4 hours.  
Nuclear and cytoplasmic fractions were separated, and immunoprecipitated with antibodies specific for GR, SMRT, 
and HDAC1.  This is a best representative western blot.  As a negative control, nuclear lysates were 
immunoprecipitated with IgG (lane 1).  GR Ab immunoprecipitates GR, SMRT, and HDAC1 (lane 2).  SMRT Ab 
immunoprecipitates SMRT, GR, and HDAC1 (lane 3).  HDAC1 Ab immunoprecipitates HDAC1, GR, and SMRT (lane 
4). 
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CHAPTER SIX 
DISCUSSION 
The data presented demonstrate that the glucocorticoid receptor interacts with HDAC1 and 
the corepressor complex SMRT within the nucleus of YT-Indy cells during dexamethasone 
treatment (figure 13).  These findings were not entirely unprecedented.  Recent work by Qiu et al. 
(2006, 2010) demonstrated that GR and HDAC1 co-precipitate in Dex-treated lysates.  Hong et al. 
(2009) determined that GR recruits SMRT to GREs during Dex-treatment.  SMRT is also known to 
bind HDAC179.  While such associations have been documented, this work is the first to 
demonstrate interactions among all three proteins, GR, SMRT, and HDAC1, in an NK-like cell line.  
Others have shown that GR interacts with HDAC237 and HDAC378, as well as NCoR78.  Contrary to 
those studies, the data demonstrate that GR does not appear to interact with NCoR, HDACs 2 or 3 
in YT-Indy cells during dexamethasone treatment (figure 12).   
Some of the reported interactions, including GR binding HDAC1 and GR recruiting SMRT, 
were found in cell lines expressing these proteins from transfection vectors.  While such data 
should not be discounted, interactions need to be confirmed in non-transfected cells; the data 
presented here demonstrates that GR binds both HDAC1 and SMRT in a cell line expressing these 
proteins from the genome.  Additionally, the interactions documented in this study were found 
using a cell line, which can model physiological conditions and allow for development of methods 
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and materials to test primary cells and cells ex vivo, in order to confirm these findings in 
physiological settings. 
The interaction among GR, these corepressor complexes, and these HDACs have been 
found in a variety of cell types76-79, suggesting that recruitment of specific complexes and HDACs 
by GR may be context dependent.  As GR has been shown to interact with both NCoR and 
SMRT78, the preference for one corepressor over the other may be due to differences in the 
subcellular environment among different cell types.  Interaction between hormone nuclear 
receptors like GR and corepressor complexes depend on a number of factors, including the direct 
binding between GR and the corepressor’s interacting domains, as well as the composition of the 
corepressor complex.  It is feasible that different proteins are part of the SMRT or NCoR 
complexes in different cell types; perhaps in YT-Indy cells, another protein blocks the sites where 
GR is capable of binding NCoR, but those sites are available on SMRT.  This may also explain 
SMRT’s recruitment of HDAC1 instead of HDACs 2 or 3; the site HDAC1 binds in the SMRT 
complex may be exposed, while the sites for HDACs 2 or 3 are not in this context. 
In the nuclei of YT-Indy cells treated with Dex (figure 13), GR precipitates SMRT and 
HDAC1 (lane 2), SMRT precipitates GR and HDAC1 (lane 3), and HDAC1 precipitates GR and 
SMRT (lane 4).  This demonstrates that GR binds with both HDAC1 and SMRT; however, the order 
of binding was not determined.  However, HDAC1 only precipitates GR, and not SMRT in Dex-
treated whole cells (figure 12, lane 5).  This raises the possibility that HDAC1 may be binding GR 
itself, without SMRT, and from the immunoprecipitation data presented here, the order of 
interaction cannot be determined.  Others have reported direct interactions between GR and 
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HDAC177.  The proposed model suggests that interaction between GR and a corepressor complex, 
SMRT in this instance, recruits the HDAC, HDAC1 in this instance.  The data supports such a 
model, as all three have been shown to interact, but the possibility still exists that HDAC1 binds GR 
directly.  SMRT may recruit HDAC1 to GR initially, and HDAC1 may bind GR directly after the initial 
recruitment.  The interaction between SMRT and GR may also be maintained after HDAC1 binds 
GR itself, as SMRT may recruit other factors, perhaps proteins with kinase activity to 
dephosphorylate histone residues.  Further testing is required to determine the order of interaction, 
as well as to demonstrate GR’s recruitment of SMRT and HDAC1 to chromatin specifically. 
Another finding of this work is the characterization of the subcellular localization of the 
glucocorticoid receptor during the first eight hours of treatment (figure 8).  As anticipated, the 
majority of GR is within the cytoplasm of non-treated cells (figure 8A, lane 2 as compared to lane 
1).  On average, 74% of GR is in the cytoplasm (figure 8B).  Unactivated GR (without ligand) is 
more often found in the cytoplasm; however, unactivated GR is known to shuttle between the 
cytoplasm and nucleus, depending on the accessibility of its nuclear localization sequence and 
nuclear retention signal41,42,44.  This may account for 26% of total cellular GR that is within the 
nucleus of untreated cells.  Additionally, the YT-Indy cell line was cultured in supplemented media, 
which may contain some factor that may reveal GR’s NLS, allowing for translocation into the 
nucleus in the absence of ligand. 
While GR is in the cytoplasm of untreated cells, Dex treatment induces a shift of GR into 
the nucleus, as early as 2 hours (figure 8A, lane 3).  With 4 hours of treatment, a reversal from the 
untreated condition is observed (figure 8B); the majority of GR is in the nucleus at 4 hours.  By 8 
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hours, the majority of GR returns to the cytoplasm.  With 24 hours of treatment, GR is divided 
equally between the nucleus and cytoplasm (data not shown), indicating that GR continues to 
shuttle between compartments throughout treatment.  GR’s presence within the nucleus at 4 hours 
has been demonstrated previously80,71, as has GR’s localization in both the nucleus and the 
cytoplasm during Dex treatment37. 
The presence of GR within a particular subcellular compartment was determined using 
both western blot and immunocytochemical analysis.  The work presented herein analyzed western 
blots to quantify the level of GR in each compartment during time points ranging from 0 to 24 
hours.  The quantitative analysis of GR western blot images encountered some challenges.  First, 
GR is reported to be a 97 kDa protein that undergoes various post-transcriptional modifications, 
including phosphorylation, acetylation, and ubiquitination39, and is known to have up to eight 
isoforms of varying size81.  Therefore, several band heights were detected in molecular weight 
range between 95 kDa and 100 kDa (figure 8A).  Acetylation occurs in the cytoplasm prior to 
translocation into nucleus30, which may account for the doublet that appears in the cytoplasmic 
fraction of untreated cells (lane 2, figure 8A), where GR molecules exist in both the acetylated and 
unacetylated forms.  Transport of liganded GR occurs to the acetylated forms only; thus, only the 
higher molecular weight band, the acetylated form, is seen in the nuclear fraction of these 
untreated cells (lane 1, figure 8A).  Furthermore, in the cytoplasm of cells treated with Dex, GR’s 
ligand, the unacetylated predominates (lane 4, 6, 8), as the acetylated form would translocate into 
the nucleus upon binding to ligand, which is abundant in the Dex-treated cells.  In addition to 
varying molecular weights, the quantities of GR between time points are not consistent; the level 
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found in the untreated cells appears to be much greater than the levels in Dex-treated cells.  
Dexamethasone is known to decrease the level of GR within the cell by both inhibiting transcription 
of the GR locus39 as well as by increasing proteosomal degradation of GR45. 
In addition to the subcellular localization of GR, HDACs 1, 2, and 3 were evaluated in YT-
Indy cells.  As figure 9 depicts, HDAC1 is present in both the nucleus (56%) and cytoplasm (45%) 
of untreated cells, which is consistent with the literature82.  Dex initially increases the proportion of 
HDAC1 found in the nucleus at 2 and 4 hours of treatment.  At 8 hours of treatment, HDAC1’s 
subcellular localization returns to the pattern found in untreated cells.  To date, the effect of 
dexamethasone treatment on the subcellular localization of HDAC1 has yet to be presented in 
literature. 
As previously stated, HDAC1 is known to exist in both the nucleus and the cytoplasm; 
HDAC1 requires a shuttle protein for export from the nucleus59.  The initial increase in HDAC1 in 
the nucleus during the first 4 hours of Dex treatment may be caused by preventing interaction 
between HDAC1 and its shuttle protein.  HDAC1 is known to interact with many multi-protein 
complexes including ligand bound GR.  It is conceivable that interactions between HDAC1 and GR 
or other complexes may prevent association with its shuttle protein.  As GR dissociates from 
HDAC1 to exit the nucleus by 8 hours, HDAC1’s shuttle protein may bind and escort HDAC1 to the 
cytoplasm, returning the protein to localization similar to untreated cells. 
HDAC2 is also found in both the nucleus (52%) and cytoplasm (48%) of untreated YT-Indy 
cells (figure 10), as is consistent with the literature82.  Dex significantly increases the proportion of 
53 
 
 
 
HDAC2 in the nucleus at 2 hours (71%), followed by a return to a more equal distribution between 
both compartments at 4 and 8 hours of treatment. 
Nuclear HDAC2 peaks at 2 hours and subsequently decreases; this initial increase 
coincides with the increase observed with HDAC1.  HDACs 1 and 2 are known to associate with 
each other78 in multiple protein complexes; thus, the initial retention of HDAC1 may also result in 
the initial increase in HDAC2 in the nucleus.  Then, as increasing levels of ligand bound GR enters 
the nucleus (peaking at 4 hours of treatment), GR recruitment of HDAC1 may cause HDAC1 to 
dissociate from HDAC2.  Upon interacting with GR, HDAC1 is acetylated, which decreases 
interaction with HDAC279. 
As determined previously82, HDAC3 is present in both the nucleus and cytoplasm of YT-
Indy cells (figure 11).  HDAC3 favors nuclear localization (57% - 66%) in both untreated and Dex-
treated cells at all time points, indicating that dexamethasone does not impact the subcellular 
localization of HDAC3, unlike HDACs 1 and 2.  While HDACs 1 and 2 are often reported to be 
bound together in the nucleus58, HDAC3 is not localized with either HDAC 1 or 258.  It is possible 
that GR’s recruitment of HDAC1 impacts HDAC2 localization patterns as they are often associated 
in the nucleus58,78,79, but not HDAC3 due to the lack of HDAC1 and HDAC3 binding. 
  While dexamethasone treatment impacts the localization of HDACs 1 and 2, the data 
presented demonstrate that HDACs 1, 2, and 3 are all present in the nucleus when GR’s nuclear 
localization peaks at 4 hours.  Therefore, all three HDACs are available to interact with GR during 
dexamethasone treatment, and the impact of these HDACs on GR cannot be ruled out by changes 
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in localization alone.  However, the retention of HDAC1 in the nucleus overlaps the time point with 
peak levels of nuclear GR, perhaps creating optimal conditions to allow for interaction between 
these two proteins. 
The findings presented confirm that dexamethasone inhibits the natural killer cell activity of 
the YT-Indy cell line (figure 7).  While this trend is well-established in many cell types in the 
literature5,6,9,72,73, the data here confirms that the phenomenon extends to the YT-Indy line as well.  
Dex significantly decreases the ability of YT-Indy cells to lysis target tumor cells in a time 
dependent manner as early as 8 hours, with the greatest inhibition observed with 24 hours of 
treatment. 
The lytic activity of YT-Indy cells is enhanced over time by incubating in culture media 
(figure 7).  A significant increase in NK cell activity is observed between 4 and 8 hours of culture.  
The increased NKCA can be contributed to the presence of fetal bovine serum in the media, as it 
has previously been shown that cytotoxic activity of NK cells is enhanced by fetal bovine serum96.  
Fetal bovine serum contains numerous cytokines, including IL-2, IL-6, and IL-12, which are known 
to activate NK cells97.  Activation of NK cells increases the production of cytokines and effector 
molecules97, including granzymes and perforin, which contribute to NK cytotoxic activity.  Fetal 
bovine serum also contains low levels of IgG, which activates NK cells via the Fc receptor97.  
Culturing in fetal bovine serum has been shown to continuously increase NK cell cytolytic activity 
over time96.  From the data presented in figure 7, YT-Indy cytolytic activity is enhanced by culturing 
with fetal bovine serum, similar to human NK cells.        
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In addition to the findings presented, Dex treatment has been shown to diminish secreted 
and intracellular levels of both perforin and IFN-γ in another NK-like cell line9.  Treatment of YT-
Indy cells with Dex also reduced acetylation of the H4-K8 residue with 8 hours of treatment 
(supplemental figure 1).  Previous work demonstrated that acetylation of H4-K8 residues in the 
promoter regions of IFN-γ and perforin genes was also decreased by dexamethasone treatment9. 
Taken together with these additional findings, the data presented within suggest that 
glucocorticoids, like dexamethasone, enter the cell and induce translocation of the glucocorticoid 
receptor into the nucleus, maximally at 4 hours of treatment.  Within the nucleus, GR recruits 
SMRT and HDAC1, which deacetylates H4-K8 residues in the promoter regions of effector genes, 
including perforin and IFN-γ.  The decrease in acetylation of gene promoters results in fewer 
effector molecules produced and secreted.  Fewer effector molecules results in reductions in the 
ability of NK cells to lyse target cells.  
The experimental approach and data presented here can only suggest that HDAC1 is the 
enzyme responsible for the deacetylation of H4-K8 reported.  Further studies are required to 
determine if HDAC1 binds, either directly or indirectly, to promoter regions of NK cell effector 
genes.  Additionally, HDAC1’s enzymatic activity in YT-Indy cells during dexamethasone treatment 
must also be tested.  Furthermore, histone deacetylases are not the only factors to impact histone 
acetylation status, as histone acetyltransferases are responsible for making the acetylation mark.  
GR has also been reported to inhibit the activity of HAT complexes34; additional testing is required 
to determine the contributions of HDACs versus HATs to the decrease in histone acetylation levels 
during Dex treatment.  
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Acetylation of H4-K8 
 
 
 
 
Supplemental figure 1.  Acetylation of H4-K8.  YT-Indy cells were cultured in the presence and absence of 
dexamethasone for 4, 8, and 24 hours.  Cell lysates were analyzed by immunoblot, using an antibody specific for 
acetylated H4-K8.  No change in the level of H4-K8 acetylation between untreated cells at 4 hours (lane 4) or 24 hours 
(lane 3).  No difference in H4-K8 acetylation is observed between untreated cells (lanes 3 and 4) and 4 hour treatment 
(lane 2).  At 8 hours of Dex treatment (lane 1), H4-K8 acetylation is decreased. 
Courtesy Karen Krukowski (unpublished data). 
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